Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

The AcQCross Qx system combines the dilator and needle needed to perform left-atrial appendage closure procedures, eliminating the need to swap equipment mid-surgery while crossing into the left side of the heart. (Pixabay)

News | Left Atrial Appendage (LAA) Occluders

Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

December 22, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

December 22, 2022

Robbin Cohen, MD, now serves as director of the Cardiac Surgery Program at Huntington Health, a Cedars-Sinai affiliate, and will be practicing out of Huntington Health’s Pasadena campus.

News | Cardiovascular Surgery

Cedars-Sinai Expands Cardiac Surgery at Huntington Health

December 21, 2022 — The Smidt Heart Institute at Cedars-Sinai is again expanding its geographic reach and surgical ...

December 21, 2022

Arrow International, LLC, a Subsidiary of Teleflex, Inc, recalls Arrow AutoCAT 2, AC3 intra-aortic balloon pumps for unexpectedly short battery run times

Feature | Intra-Aortic Balloon Pumps (IABP)

Teleflex Recalls Arrow Intra-Aortic Balloon Pumps for Short Battery

The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Arrow AutoCAT 2 and AC3 Intra-Aortic ...

December 20, 2022

Late-breaking clinical trials for the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.23/WCC) have been announced.

Feature | ACC | By Melinda Taschetta-Millane

ACC 2023 Late-breaking Clinical Trials Announced

Late-breaking clinical trials for the American College of Cardiology’s Annual Scientific Session Together with World ...

December 20, 2022

suPAR overexpression leads to increased atherosclerotic and necrotic plaques in a murine model of atherosclerosis. WT (n = 18) and suPARTg (n = 21) mice were maintained on a low-fat diet until 3 months of age and were then transfected with Pcsk9-AAV and fed a western diet (WD) for 10 weeks. At this point, aortic roots were obtained, paraffin embedded, and stained with H&E and Mac2 (galectin 3). (A) Cross sections of aortic roots from C57BL/6 WT and suPARTg mice show total lesion area, outlined in dashed lin

News | Heart Failure

New Immune Target to Treat Cardiovascular Disease Discovered

December 16, 2022 — For the longest time, clinicians have treated cardiovascular disease by focusing on diabetes and ...

December 16, 2022

Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients living with a common genetic condition that causes very high levels of unhealthy cholesterol, heightening the risk for heart attacks and strokes even at a young age.

News | STEMI

Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition

December 15, 2022 — Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation ...

December 15, 2022

From left, Qian Ma, PhD, and Yuqing Huo, MD, PhD. Photo courtesy of Michael Holahan, Augusta University

News | Heart Failure

New Target in the Fight Against Heart Disease

December 15, 2022 — Soon after cholesterol and fat start depositing on the lining of the blood vessels that supply your ...

December 15, 2022

Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).

News | Heart Valve Technology

Edwards Identifies Top Data Releases of 2022 that Highlight the Impacts of Aortic Stenosis Undertreatment

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping ...

December 14, 2022

Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry

News | Atrial Fibrillation

Field Medical and CardioNXT Collaborate to Deliver Novel Integration of Focal Pulsed Field Ablation And 3D Mapping & Navigation For Treatment of Cardiac Arrhythmias

December 14, 2022 — Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of ...

December 14, 2022

Corindus, A Siemens Healthineers Company, has officially rebranded as Siemens Healthineers

News | Cardiovascular Business

Corindus, A Siemens Healthineers Company, Is Now Siemens Healthineers Endovascular Robotics

December 14, 2022 — Corindus, A Siemens Healthineers Company, has been rebranded to Siemens Healthineers Endovascular ...

December 14, 2022

Series to feature leading experts discussing the current and future trends in the carotid treatment market

News | Stents Carotid

InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

December 13, 2022

Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.

News | Structural Heart

Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

December 13, 2022

Image courtesy of Intermountain Healthcare

News | Cardiovascular Clinical Studies

Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

December 13, 2022

The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between 2022 and 2025, driven by increasing population at a risk of cardiovascular diseases.

News | Pacemakers

Global Pacemakers Market Set to Grow at 5.4% CAGR Over Next 3 Years

December 12, 2022 — The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between ...

December 12, 2022

News | Cardiovascular Business

Edwards Lifesciences Announces CEO Succession Plan

December 12, 2022 — Edwards Lifesciences Corporation announced that following regular succession planning discussions ...

December 12, 2022